Emerald Mutual Fund Advisers Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,530	Closed	-$148K	–	232
2023 Q4	$148K	Buy	1,530 +582	+61%	+$51.5K	0.01%	225
2023 Q3	$83.9K	Sell	948 -21	-2%	-$1.87K	0.01%	226
2023 Q2	$84K	Buy	+969	New	+$91.2K	﹤0.01%	229
2023 Q1	–	Sell	-1,049	Closed	-$109K	–	221
2022 Q4	$109K	Buy	+1,049	New	+$98.5K	0.01%	198

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's BMRN Position: Q1 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 1,530 shares — an estimated $148K sold.

Emerald Mutual Fund Advisers Trust first reported a position in BMRN in Q4 2022 and held it in 4 quarters. The position peaked at $148K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Emerald Mutual Fund Advisers Trust reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 1,530 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $148K.
Emerald Mutual Fund Advisers Trust first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Emerald Mutual Fund Advisers Trust's BioMarin Pharmaceuticals position peaked at $148K in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2024, filed 8 May 2024.